Free Trial

TherapeuticsMD 11/12/2024 Earnings Report

TherapeuticsMD logo
$0.98 -0.07 (-6.48%)
As of 03/28/2025 04:00 PM Eastern

TherapeuticsMD EPS Results

Actual EPS
-$0.05
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

TherapeuticsMD Revenue Results

Actual Revenue
$0.55 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

TherapeuticsMD Announcement Details

Quarter
Time
After Market Closes

Conference Call Resources

Remove Ads

TherapeuticsMD Earnings Headlines

TherapeuticsMD Announces Full Year 2024 Financial Results
URGENT: Someone's Moving Gold Out of London...
People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “gold analysts” have it all wrong… They tell you to invest in gold ETFs - because the popular mining ETFs will someday catch fire and close the price gap with spot gold.
TherapeuticsMD Shifts Focus with Lower Q3 Losses
See More TherapeuticsMD Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like TherapeuticsMD? Sign up for Earnings360's daily newsletter to receive timely earnings updates on TherapeuticsMD and other key companies, straight to your email.

About TherapeuticsMD

TherapeuticsMD (NASDAQ:TXMD) operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

View TherapeuticsMD Profile

More Earnings Resources from MarketBeat